Related Experiment Video

Updated: May 6, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.3K

The effects of Tissue-type Plasminogen Activator on PSC Activation

Min Zha1, Yi Wei1, Shu Zhang1

  • 1Department of Endocrinology, Jiangsu Province Hospital of Chinese medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Hanzhong Road, Nanjing, China.

Endocrine, Metabolic & Immune Disorders Drug Targets
|May 5, 2026
PubMed
Abstract

Insights

Tissue-type plasminogen activator (tPA) inhibits pancreatic stellate cell (PSC) activation, proliferation, and migration. Reduced tPA in type 2 diabetes mellitus (T2DM) may worsen islet damage by promoting PSC activity.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Biochemistry

Background:

  • Activated pancreatic stellate cells (PSCs) contribute to islet damage in type 2 diabetes mellitus (T2DM).
  • Tissue-type plasminogen activator (tPA) levels are reduced in T2DM, but its role in PSC activation is unknown.

Purpose of the Study:

  • To investigate the impact of tPA on PSC activation.
  • To elucidate the potential role of tPA in T2DM pathogenesis.

Main Methods:

  • Quantified tPA levels in T2DM patients and healthy controls using ELISA.
  • Isolated and characterized rat PSCs.
  • Assessed PSC proliferation, apoptosis, migration, and extracellular matrix (ECM) synthesis after tPA treatment via CCK-8, caspase-3 assay, wound-healing, transwell assays, and Western blot.

Main Results:

  • T2DM patients exhibited significantly lower tPA levels than controls.
  • tPA treatment inhibited PSC proliferation, migration, and ECM synthesis.
  • tPA treatment led to increased lipid droplet accumulation in PSCs.

Conclusions:

  • tPA significantly inhibits PSC activation, proliferation, migration, and ECM synthesis.
  • Reduced tPA in T2DM may exacerbate PSC-mediated islet damage, impairing β-cell function.
Keywords:
Pancreatic stellate cellactivationclinical researchextracellular matrixtissue-type plasminogen activatortype 2 diabetes mellitus

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.3K
Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

9.4K

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
663
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.0K